OSE Immunotherapeutics is a biotechnology company dedicated to the development of innovative immunotherapies which act on effector and suppressor cells to stimulate or inhibit the body's immune response, and to restore immune disorders in the fields of immuno-oncology, autoimmune diseases and transplantation.
OSE Immunotherapeutics focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases.
OSE Immunotherapeutics was founded in 2012 & is based in Nantes, Pays de la Loire, France.
OSE Immunotherapeutics has several scientific and technological platforms, neoepitopes, monoclonal antibodies agonists or antagonists, ideally positioned to fight cancer and autoimmune diseases. Its leading clinical portfolio has a diversified risk profile.
OSE Immunotherapeutics is backed by Bpifrance. The company went public on Sep 11, 2015, OSE Immunotherapeutics has also acquired Effimune SAS on Feb 24, 2016.